Literature DB >> 12696209

Thalidomide: current therapeutic uses and management of its toxicities.

Joseph D Tariman1.   

Abstract

Thalidomide currently is used to treat relapsed and refractory multiple myeloma. The drug also is being actively investigated in patients newly diagnosed with multiple myeloma. The therapeutic applications of thalidomide are expected to grow as clinical trials document its activity in treating other neoplastic disorders and diseases. Healthcare providers need to be well informed of its toxicities and able to identify their signs and symptoms immediately. They must have adequate knowledge about thalidomide administration and provide comprehensive patient education regarding thalidomide and its toxicities to ensure patient safety and compliance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12696209     DOI: 10.1188/03.CJON.143-147

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  5 in total

Review 1.  The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing.

Authors:  Anna Liza Rodriguez; Joseph D Tariman; Toreend Enecio; Stella Marie Estrella
Journal:  Clin J Oncol Nurs       Date:  2007-08       Impact factor: 1.027

2.  Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Joseph D Tariman; Ginger Love; Emily McCullagh; Stacey Sandifer
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

3.  Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease.

Authors:  S Prasad Gabbita; Minu K Srivastava; Pirooz Eslami; Ming F Johnson; Naomi K Kobritz; David Tweedie; Nigel H Greig; Frank P Zemlan; Sherven P Sharma; Marni E Harris-White
Journal:  J Neuroinflammation       Date:  2012-05-25       Impact factor: 8.322

4.  Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma.

Authors:  Ibrahim A Darwish; Nourh Z Alzoman; Reem M Abuhejail; Tilal E El-Samani
Journal:  Chem Cent J       Date:  2012-10-26       Impact factor: 4.215

5.  Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine.

Authors:  Nasr Y Khalil; Ibrahim A Darwish; Tanveer A Wani; Abdel-Rahman A Al-Majed
Journal:  Chem Cent J       Date:  2013-03-14       Impact factor: 4.215

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.